Omega-3 and omega-6 fatty acids and type 2 diabetes

Current Diabetes Reports

Volumn 13, Issue 2, 2013, Pages 279-288

  Jeppesen, Charlotte ^a   Schiller, Katja ^a   Schulze, Matthias B ^a  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Cardiovascular disease; Intermediate outcomes; Microvascular complications; Mortality; Omega 3 fatty acids; Omega 6 fatty acids; Type 2 diabetes

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84878649318     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0362-8     Document Type: Article

References (31)

1. IDF: http://www.idf.org/diabetesatlas. International Diabetes Federation (2011); 5. Accessed Nov 2012.
2. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41.
3. ADA. http://www.diabetes.org/. American Diabetes Association (2012). Accessed Nov 2012.
4. Dyerberg J. H.O B. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975;28:958-66.
5. Young TK, Bjerregaar P, editors. Health transitions in arctic populations. Toronto: Toronto Press; 2008.
6. AHA. American Heart Association: http://www.heart.org/HEARTORG/General/ Frequently-Asked-Questions-About-Fish-UCM-306451-Article.jsp (2012). Accessed Nov 2012.
7. Hu FB, Cho E, Rexrode KM, et al. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation. 2003;107(14):1852-7.
8. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223- 30.
9. • Kromhout D, Geleijnse JM, de Goede J, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34(12):2515-20. Contains a sub-group analysis of the two-by-two factorial deigned OMEGA trial including 1014 high-risk diabetic patients with previous MI. The participants were supplemented with 223 mg EPA + 149 mg DHA and/or 1.9 g ALA. The study found a protective effect against ventricular arrhythmia related events and fatal MI.
10. • ORIGIN JB, Gerstein HC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-18. A large randomized supplementation trial among 12,536 patients with impaired glucose tolerance and type 2 diabetic patients with a follow-up period of 6.2 years. The participants received 1 g omega-3 FA/d (465 mg EPA and 375 mg DHA) or placebo (olive oil 1 g/d). The study found no significant effect on rates of major vascular events, death from any cause or death from arrhythmia. Only triglycerides were reduced in the omega-3 FA group compared to olive oil, but no other lipids were affected.
11. AHA. American Heart Association: http://www.heart.org/HEARTORG/ Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes-UCM- 313865-Article.jsp. Accessed December 2012.
12. Czernichow S, Thomas D, Bruckert E. n-6 Fatty acids and cardiovascular health: A review of the evidence for dietary intake recommendations. Br J Nutr. 2010;104(6):788-96.
13. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015-26.
14. Dijkstra SC, Brouwer IA, van Rooil FJA, et al. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail. 2009;11:922-8.
15. Adler AI, Boyko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care. 1997;20(7):1162-7.
16. Bruce SG, Young TK. Prevalence and risk factors for neuropathy in a Canadian First Nation community. Diabetes Care. 2008;31(9):1837-41.
17. Horrobin DF. Essential fatty acids in the management of diabetic neuropathy. In: Huang Y-S, Mills DE, editors. Gamma-Linolenic Acid Metabolism and Its Roles in Nutrition and Medicine. Champaign, Illinois: AOCS Publishing; 1996. doi: 10.1201/9781439831939.ch21
18. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: A double-blind placebo-controlled trial. Diabet Med J Br Diabet Assoc. 1990;7(4):319-23.
19. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16(1):8-15.
20. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-83.
21. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158(9):998-1004.
22. Evans TC, Capell P. Diabetic Nephropathy. Clin Diabetes. 2000;18. http://journal.diabetes.org/clinicaldiabetes/v18n12000/Pg7.htm. Accessed December 2012.
23. O'Connor AS, Schelling JR. Diabetes and the kidney. Am J Kidney Dis. 2005;46(4):766-73.
24. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. J Am Diet Assoc. 2005;105(3):428-40.
25. Miller ER, Juraschek SP, Appel LJ, et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-Analysis of clinical trials. Am J Clin Nutr. 2009;89(6):1937-45.
26. • Hartweg J, Farmer AJ, Holman RR, et al. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol. 2009;20(1):30-8. A meta-Analysis on omega-3 FA treatment among T2DM patients on cardiovascular risk factors. The analysis pooled data from 24 trials from 1966-2008 involving 1533 patients receiving 2.4 g omega-3 FA/d for average 24 weeks. The study found that triglycerides, fibrinogen, ADP platelet aggregation and collagen were decreased with omega-3 supplementation whereas LDL-cholesterol was increased.
27. Wong CY, Yiu KH, Li SW, et al. Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med J Br Diabet Assoc. 2010;27(1):54-60.
28. Rajala U, Paivansalo M, Laakso M, et al. Associations of blood pressure with carotid intima-media thickness in elderly Finns with diabetes mellitus or impaired glucose tolerance. J Hum Hypertens. 2003;17:705-11.
29. Brohall G, Schmidt C, Behre CJ, et al. Association between impaired glucose tolerance and carotid atherosclerosis: A study in 64-year-old women and a meta-Analysis. Nutr Metab Cardiovasc Dis. 2009;19(5):327-33.
30. Mita T, Watada H, Ogihara T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191:162.
31. Moghadam M, Saedisomeolia A, Djalali M, et al. Efficacy of omega-3 fatty acid supplementation on serum levels of tumor necrosis factor- Alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Singap Med J. 2012;53:615-9.